Italia markets closed

PFE Jun 2026 40.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,9800+0,0300 (+3,16%)
In data: 03:02PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,9500
Aperto0,9000
Denaro0,9000
Domanda1,1200
Prezzo d'esercizio40,00
Scadenza2026-06-18
Min-Max giorno0,9000 - 0,9800
Contratto - Min-MaxN/D
Volume2
Open Interest7,01k
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g